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ABSTRACT  
    Activation of the inflammasome is implicated in the pathogenesis of an increasing number 
of inflammatory diseases, including Alzheimer's disease (AD). Research reporting 
inflammatory changes in post mortem brain tissue of individuals with AD and GWAS data 
have convincingly demonstrated that neuroinflammation is likely to be a key driver of the 
disease.  This, together with the evidence that genetic variants in the NLRP3 gene impacts on 
  
the risk of developing late-onset AD, indicates that targetting inflammation offers a 
therapeutic opportunity.  Here, we examined the effect of the small molecule inhibitor of the 
NLRP3 inflammasome, MCC950, on microglia in vitro and in vivo. The findings indicate that 
MCC950 inhibited LPS+Aβ-induced caspase 1 activation in microglia and this was 
accompanied by IL-1β release, without inducing pyroptosis. We demonstrate that MCC950 
also inhibited inflammasome activation and microglial activation in the APP/PS1 mouse 
model of AD.  Furthermore, MCC950 stimulated Aβ phagocytosis in vitro, and it reduced Aβ 
accumulation in APP/PS1 mice, which was associated with improved cognitive function. 
These data suggest that activation of the inflammasome contributes to amyloid accumulation 
and to the deterioration of neuronal function in APP/PS1 mice and demonstrate that blocking 
assembly of the inflammasome may prove to be a valuable strategy for attenuating changes 
that negatively impact on neuronal function.  
 
KEY WORDS: Microglia, interleukin-1β, caspase 1, inflammasome, APP/PS1 mice, 
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1. INTRODUCTION 
    Recent GWAS data highlighted the importance of neuroinflammation as a factor that 
contributes to the pathogenesis of Alzheimer's disease (AD). These findings identified that 
mutations in genes specific to microglia/myeloid cells confer a significant risk of developing 
the sporadic form of AD (Karch and Goate, 2015), validating previous evidence that linked 
increased activation of microglia and production of inflammatory mediators, including 
interleukin-1β (IL-1β), with AD (Griffin et al., 1989).  
    Production of IL-1β is primarily dependent on activation of the inflammasome, a complex 
of cytosolic proteins that assemble in response to several factors.  Among these factors are 
reactive oxygen species and also misfolded proteins that trigger lysosomal rupture and 
cathepsin release (Haneklaus and O'Neill, 2015; Man and Kanneganti, 2015). Several 
inflammasomes have been described but the NLRP3 inflammasome is best described, 
and its activation is now recognized as a central component in the development of several 
inflammatory and autoimmune diseases.  
    Amyloid-β (Aβ) peptide, which accumulates to form the characteristic plaques in AD, 
activates the NLRP3 inflammasome. It is engulfed by cells and the consequent lysosomal 
activation and cathepsin B release triggers assembly of the inflammasome, activation of 
caspase 1 and release of IL-1β (Halle et al., 2008). These data suggested a possible role for 
the inflammasome in AD and the observation that NLRP3-deficiency in the APP/PS1 mouse 
model decreased neuroinflammation and Aβ accumulation, and improved neuronal function, 
supports this hypothesis (Heneka et al., 2013).  Notably, expression of several components of 
the inflammasome, including NLRP3 and caspase 1 as well as IL-1β and IL-18, is increased 
in monocytes from AD patients, and to a lesser extent from patients with mild cognitive 
impairment (Saresella et al., 2016).  Recent evidence suggests that the rs10754558 variant of 
the NLRP3 gene confers a significant risk of late-onset AD, particularly in ApoE ε4 carriers 
and while the rs2027432 variant is also associated with increased risk, the rs35829419 variant 
(Q705K in NLRP3) is associated with protection (Tan et al., 2013). 
    A recently-described small molecule inhibitor of the NLRP3 inflammasome, MCC950, 
has been shown to increase survival, and decrease serum IL-18, in a mouse model of 
cryopyrin-associated periodic syndrome (CAPS) (Coll et al., 2015). These syndromes are 
rare, inherited, autoinflammatory diseases that are caused by autosomal-dominant 
mutations of the NLRP3 gene.  They are characterized by systemic inflammation of 
  
several organs, including brain, as a result of inappropriate cryopyrin-driven 
inflammasome activation and IL-1β production (Mortimer et al., 2016).  MCC950 is a 
diarylsulphonylurea-containing compound that was originally shown to reduce 
ATP+LPS-induced mature IL-1β production in monocytes and macrophages; it was 
recognized that the compounds, which included MCC950 (then called CRID), acted 
independently of the stimulus (Perregaux et al., 2001). 
    Coll and colleagues also showed that MCC950 reduced the severity of symptoms in an 
animal model of multiple sclerosis (Coll et al., 2015). This was attributed to the reduction in 
IL-1β-induced activation of γδ T cells, and consequently IL-17 production by CD4+ T cells; 
MCC950 suppressed IL-1β production by dendritic cells and macrophages, which together 
with IL-23, is required for IL-17 production by γδ and Th17 cells (Sutton et al., 2009).  
    Here, we investigated the effect of MCC950 in the APP/PS1 mouse model of AD and 
show that it improves cognitive function and reduces both Aβ accumulation and microglial 
activation. MCC950 prevented inflammasome activation and IL-1β release from microglia 
and, at the same time, promoted Aβ phagocytosis.  The data suggest that inhibiting NLRP3 
inflammasome assembly may be key to limiting the pathology in AD. 
 
2. MATERIALS AND METHODS  
Animals 
    Neonatal C57/BL6 mice were used to prepare cultured microglia. For the in vivo 
experiments, we used male and female wildtype and APPswe/PS1dE9 mice (hereafter 
referred to as APP/PS1 mice). This double transgenic mouse model was produced by co-
injection into pronuclei of the APP695 isoform containing the Swedish mutation and 
PS1 with exon-9 deleted.  Each gene was under the control of an independent PrP 
promoter (Jankowsky et al., 2001). All experiments were performed under license from the 
Health Products Regulatory Authority of Ireland in accordance with EU regulations and with 
local ethical approval (Trinity College Dublin). Animals were housed under controlled 
conditions (20-22°C, food and water ad lib) and maintained under veterinary supervision.   
Treatment schedule 
    Wildtype and APP/PS1 mice (12 months at the start of the study) were subdivided into 
MCC950- and control-treated groups and experiments were carried out in 2 batches, 
separated by 6 months. The numbers of male and female mice in the wildtype control-
treated and MCC950-treated groups were 7 and 4, and the numbers of male and female 
mice in the APP/PS1 control-treated and MCC950-treated groups were 4 and 7, and 4 
and 8 respectively. Details with respect to the production of the preparation of MCC950 
used here is described in detail previously (Coll et al., 2015). Mice received intraperitoneal 
injections of sterile PBS (control) or MCC950 (10 mg/kg in PBS) every second day for 3 
months and in the 8th and 9th week of treatment, their performance in a T-maze and a novel 
object recognition task was assessed. At the end of the 3-month treatment, mice were 
anaesthetized, transcardially perfused and the brain was removed (Minogue et al., 2014). One 
half was stored for later preparation of sections for immunohistochemistry, and the 
hippocampus and cortex were dissected free from the other side of the brain and flash frozen 
for later analysis.  
Behavioural analysis 
    To assess behaviour in the spontaneous alternation in the T-maze, mice were placed in the 
start area and allowed to freely explore the left or right arm of the maze. Once a mouse had 
entered one of the target arms, the door to the arm was closed, the mouse remained in the arm 
for 30 seconds, after which time the test was repeated with the doors open. Cognitively-
healthy mice usually enter the previously-unexplored arm. After each trial the mouse was 
  
placed back in its cage and tested again after all other animals had been evaluated in the task. 
Successful alternations were recorded over 8 trials.  
    Prior to testing in the 2-object novel object recognition test, mice were habituated to the 
open field testing arena for 3 days for 5 min on day 1 and 20 min on days 2 and 3. On the 
fourth day, mice were allowed to freely explore 2 identical objects in the open field for 10 
min (training period) and, after 1h, were returned to the open field with one of the two 
original objects replaced by a novel object. The mice were allowed to freely explore both 
objects for 5 min (test period). The time spent exploring the objects was measured. The 
location preference (to assess the impact of position on preference) is described as the time 
exploring one object/total time exploring × 100% and the recognition index, assessed in the 
testing phase, is the time exploring novel object /total time exploring × 100% 
Immunohistochemistry  
    Congo red was used to identify Aβ plaques as previously described (Minogue et al., 
2014).  Briefly, sagittal sections of hippocampal tissue were equilibrated to room 
temperature, fixed in ice-cold methanol (5 min), washed, incubated (20 min) in a saturated 
NaCl solution, and then incubated (2h) in filtered Congo red solution. Slices were washed in 
dH2O, counterstained with methyl green solution (1% in dH2O; 30 sec) and rinsed with 
running dH2O for 1 min. Sections were dehydrated by immersion in 95% and subsequently 
100% ethanol, incubated in xylene (3 x 5 min) and mounted onto coverslips using dibutyl-
phthalate in xylene (DPX) (VWR, US) and allowed to set. Slices were stored at 4oC until 
required and then imaged using a microscope (Olympus DP72). The number of plaques was 
counted, approximately midway along the rostral-caudal axis, and 9 sections from each 
animal were examined. 
    To assess immunoreactivity of CD11b and CD68, sagittal sections were equilibrated to 
room temperature, fixed in PFA 4% (30 minutes), washed and incubated (1h) in 10% normal 
horse serum (NHS) to block non-specific binding and overnight in anti-CD11b or anti-CD68 
antibody (AbD Serotec, UK) 1:100 in 10% NHS to block non-specific binding and overnight 
in anti-CD11b or anti-CD68 antibody (1:100 in 10% NHS; overnight; 4oC. Sections were 
washed, incubated (1h) with the secondary antibody, washed and incubated (45 min) in ABC 
solution (Vector labs; US), washed and incubated with DAB.  Finally, sections were washed 
and dehydrated, mounted and stored as described for Congo red staining. To assess caspase 1, 
sections were incubated at 4ºC with the primary anti-caspase 1 antibody (1:250; raised in 
goat; Santa Cruz, US) followed by the Alexa Fluor® 594 donkey anti-goat IgG (1:1000) and 
mounted in ProLong®Gold with the nuclear marker DAPI (Life Technologies). Images (6 
fields/section; 3 sections from 6 animals per treatment group repeated 3 times on 
separate days) were acquired with a Zeiss AX10 Imager A1 microscope at 40X 
magnification. Analysis of the images was undertaken with ImageJ software.  
Preparation of Primary Glial Cultures 
    Microglia were prepared from neonatal C57/BL6 mice as previously described (Costello et 
al., 2015). Microglia (4x104 cells/cm2 were plated onto coverslips coated with poly-D-lysine 
(5µg/ml; Merck Millipore Ltd, UK) and, after 48h, were preincubated with LPS (1µg/ml; 
Enzo Life Sciences, UK). After 4h, MCC950 (100nM) was added followed by the addition of 
Aβ (10µM; Invitrogen, UK) 30 min later; this concentration was chosen following 
preliminary data that indicated its near-complete inhibition of LPS+Aβ-induced increase in 
IL-1β and its lack of effect on IL-6 and TNFα, and also on cytokine mRNA expression. 
Incubation continued for a further 24h before analysis.  To prepare Aβ, lyophilized Aβ1-40 
and
 
Aβ1-42 peptides (Invitrogen, UK) were dissolved in HPLC grade water to provide a 
6mg/ml stock solution, diluted to 1mg/ml using sterile PBS and allowed to aggregate (24 
h, 220 rpm, 37°C). This preparation contains both oligomers and fibrils as evidenced by 
enhanced Thioflavin T binding (data not shown).  
  
    In separate experiments, designed to assess the impact of LPS+ATP on inflammasome 
activation, cells were preincubated with LPS (1µg/ml) for 2.5h, after which time MCC950 
(100µM) was added.  Incubation continued for 30 min before addition of ATP (5mM; Sigma, 
UK) and, after a further 5h, supernatant samples were taken for analysis of IL-1β 
concentration and LDH activity. 
LDH assay 
    Samples of supernatant were used in an LDH cytotoxicity assay to assess the impact of the 
different treatments on cell viability.  Samples (50µl) or positive control solution (50 µl; 
supplied by the manufacturer) were incubated (30 min, 37oC) in 96-well plates, stop solution 
(50 µl; supplied) was added and absorbance was measured at 490nm, subtracted from 
absorbance at 680nm, and expressed a percentage of positive control.  
Analysis of cytokines by ELISA and RT-PCR  
    Cytokine concentrations were assessed in supernatant samples from cultured microglia and 
samples of cortical homogenate as previously described (Minogue et al., 2012). Briefly, 96-
well plates (Nunc-Immuno plate with Maxisorp surface, Denmark) were coated with capture 
antibody (rat anti-mouse IL-1β or goat anti-mouse IL-6 and TNFα antibody (R&D Systems, 
US) and incubated (overnight, 4ºC). Duplicate samples or standards (50µl/well) were added 
and plates were incubated (24h, 4ºC) and washed before addition of detection (biotinylated 
goat anti-mouse) antibody for (1h, room temperature). Plates were washed, incubated with 
streptavidin-horseradish peroxidase conjugate (20 min, room temperature) and washed before 
addition of substrate solution (50µl; 1:1 H2O2:tetramethylbenzidine; R&D Systems, US).  
After colour development, the reaction was stopped by adding 1M H2SO4 (25µl) and plates 
were read at 450nm (Labsystem Multiskan RC, UK).   
    Cytokine mRNA expression was assessed in isolated microglia and hippocampal tissue by 
RT-PCR as previously described (Costello et al., 2016).  In addition to analysis of 
cytokines, we also assessed mRNA expression of mannose receptor (MRC1) and 
arginase 1 (Arg 1) in hippocampal tissue as a measure of M2 activation.  The assay ID’s 
for the genes examined were: β-actin (4352341E), IL-1β (Mm00434228_m1), IL-6 
(Mm00446190_m1), TNFα (Mm00443258_m1), MRC1 (Mm00485148_m1) and Arg-1 
(Mm00475988_m1). 
Detection of soluble Aβ 
    Snap-frozen cortical tissue was homogenised in sodium dodecyl sulphate (SDS) buffer 
(1% SDS, 50mM NaCl in dH2O) containing protease and inhibitors (1%; Sigma-Aldrich, 
UK) and centrifuged at 21,500 x g for 20 minutes at 4°C. This yields a supernatant that 
contains the SDS-soluble Aβ and the insoluble material in the pellet.  Supernatant 
samples were normalized for protein and the soluble Aβ concentrations in these samples 
were determined using a MULTI-SPOT® Human/Rodent (4G8) Abeta Triplex Ultra-
Sensitive Assay (Meso Scale Discovery, USA) as per the manufacturer’s instructions. The 
plate was read using a Mesoscale Sector Imager (Meso Scale Discovery, US) and Aβ 
concentrations calculated relative to the standard curve. 
Confocal image analysis   
    Microglial cells plated onto poly-D-lysine-coated cover slips were fixed with PFA (4%; 
30 min), washed and blocked by incubation with 10% NHS and 0.1% Triton X-100 for 
1h and incubated at 4ºC with the primary antibodies anti-Iba1 (Wako, Japan 1:1000) 
and anti-Aβ (Biolegend, US, 1:500) followed by Alexa Fluor® 594 donkey anti-rabbit 
IgG (1:1000), Alexa Fluor® 488 donkey anti-mouse IgG (1:1000) and mounted in 
ProLong®Gold with the nuclear marker DAPI (Thermo Scientific, US). To assess caspase 
1 and apoptosis-Associated Speck-Like Protein Containing CARD (ASC), microglia were 
sequentially incubated anti-caspase-1 raised in goat (Santa Cruz, US 1:100) and ASC 
(Proteintech, UK, 1:250), Alexa Fluor® 488 chicken anti-rabbit IgG (1:1000) and Alexa 
  
Fluor® 594 donkey anti-goat IgG (1:1000), and mounted as above. Images (10 fields; 
40X magnification; triplicate analysis) were acquired with a Zeiss AX10 Imager A1 
microscope. Analysis of images was undertaken with ImageJ software; the number of 
Aβ+ microglia was assessed and colocalization of caspase 1 and ASC was carried out 
using the specific plug-in Colocalization Finder. Control experiments with each 
secondary antibody, alone or in combination were included and images were acquired 
sequentially on a Leica SP8 scanning confocal microscope for each fluorophore to 
eliminate cross-signal contamination. 
Analysis of Aβ engulfment by microglia 
    For analysis of the effect of IL-1β on phagocytosis, microglia (4x104 cells/cm2 were plated 
onto coverslips coated with poly-D-lysine (5µg/ml; Merck Millipore Ltd, UK).  After 48h, 
cells were preincubated with IL-1β (10ng/ml; Affymetrix eBioscience) for 24h then 
stimulated for 2h with Aβ1-40 (5µM; Invitrogen, UK), pulse centrifuged for 15s in a benchtop 
microcentrifuge to remove large aggregates. The coverslips were washed 3 times in PBS, 
fixed in 4% PFA, washed a further 3 times in PBS and stored in PBS at 4oC.  The % of Iba+ 
cells that engulfed Aβ was calculated by enumerating the total number of Iba+ cells and the 
number of Iba+ Aβ+ cells in 3D projection images generated from Z stacks using a Zeiss 
Axiovert 200M confocal microscope and processed using LSM Image Browser software.  In 
total, 402 cells were examined. 
Western immunoblotting  
    Cultured microglia were lysed (composition in mM: Tris-HCl 10, NaCl 50, Na4P2O7.H2O 
10, NaF 50, 1% Igepal, phosphatase inhibitor cocktail I and II, protease inhibitor cocktail; 
Sigma, UK), equalized for protein and added to 4x SDS sample buffer (composition: Tris-
HCl 100mM, pH 6.8, 4% SDS, 2% bromophenol blue, 20% glycerol; Sigma, UK). Samples 
were boiled at 100°C for 5 min, aliquots (15-30µg protein) were applied to 15% SDS gels 
and proteins were transferred to nitrocellulose membrane (Advansta, US) which was blocked 
in Tris-buffered saline containing 0.05% Tween® 20 (TBS-T) and 5% non-fat dried 
milk/TBS-T (1h, room temperature). Membranes were incubated overnight at 4ºC with anti-
IL-1β (Adipogen, US), anti-caspase-1 p45/p20 raised in rabbit (Cell Signaling, US) or anti-
β-actin (Sigma, UK) in 3% BSA/TBS-T, washed and incubated with a secondary anti-rabbit, 
anti-goat or anti-mouse antibody as appropriate (Jackson Immunoresearch, US) in 2% 
BSA/TBS-T for 1-2h. Immunoreactive bands were detected using WesternBright ECL 
chemiluminescent substrate (Advansta, US). Images were captured using the Fujifilm LAS-
4000 imager and densitometric analysis was carried out using ImageJ 
(http://rsb.info.nih.gov/).  
Statistical analysis  
    Data are presented as the mean ± SEM. Statistical analysis was carried out using an 
unpaired Student’s t-test, or a 2-way ANOVA and post hoc analysis using the Bonferroni 
Multiple Comparison test.  
 
3. RESULTS   
    Microglia were incubated with LPS and ATP or LPS and Aβ and both stimuli increased 
release of IL-1β Figure 1A, B) although the effect of LPS+ATP was an order of magnitude 
greater than LPS+Aβ.  MCC950 attenuated the effect of both stimuli and a significant 
interaction between MCC950 and the inflammasome activators was observed 
((F1,20)=27.13; p < 0.0001, (F1,8)=15.47; p = 0.0043, respectively) and post hoc analysis 
indicated that the significant effects of LPS+ATP or LPS+Aβ (***p < 0.001) were 
attenuated by MCC950 (+++p < 0.001 and ++p < 0.01 respectively). Analysis of cleaved IL-
1β by western immunoblotting revealed a similar LPS+Aβ-induced increase that was 
  
attenuated by MCC950 (Figure 1C). We assessed LDH release as an indicator of cell viability 
and show that LPS+ATP markedly increased LDH release (Figure 1D); a significant 
MCC950 x LPS+ATP interaction was observed ((F1,8)=70.51; p < 0.0001).  Specifically 
LPS+ATP significantly increased LDH release (***p < 0.001; Bonferroni test) and this 
was blocked by MCC950 (+++p 0.001). In contrast, LPS+Aβ had no effect on LDH 
release, either in the presence or absence of MCC950 (Figure 1E).  This indicates that cell 
death associated with inflammasome assembly is dependent on the stimulus.  LPS+Aβ 
increased TNFα and IL-6 ((F1,8)=59.11; p < 0.0001 and ((F1,8)=130.88; p < 0.0001, 
respectively; Figure 1F,G) but MCC950 exerted no modulatory effect on these cytokines and 
post hoc analysis confirmed that the significant effects on TNFα and IL-6 (p < 0.01 and 
p < 0.001 respectively) were unaffected by MCC950. Consistent with the LPS+Aβ-induced 
inflammasome activation, this stimulus also increased the caspase 1+ immunoreactivity in 
microglia and this was inhibited by MCC950; analysis revealed a significant interaction 
between the treatments ((F1,10)=5.29; p = 0.044; Figure 2B) and post hoc analysis 
revealed that MCC950 significantly decreased the LPS+Aβ-induced change (+p < 0.05).  
Similar changes were observed with caspase 1+ ASC+ microglia although these did not reach 
statistical significance (Figure 2C).  
    We examined the impact of inflammasome assembly on phagocytosis of Aβ. The image 
(Figure 3A) shows an Iba+ microglial cell (with a pink-stained nucleus) that engulfed Aβ 
(white arrows).  Analysis of the mean data showed that intracellular staining of Aβ in Iba1+ 
microglia was similar in control-, LPS+Aβ- and MCC950-treated cells, and increased when 
cells were incubated with LPS+Aβ+MCC950 (Figure 3B); the effect of MCC950 was 
significant ((F1,12)=7.93; p=0.0156) This indicates that MCC950-associated inhibition of 
inflammasome assembly increases Aβ engulfment of cells, which is consistent with our 
finding that IL-1β inhibited phagocytosis of Aβ by microglia (p < 0.05; student's t-test for 
independent means; Figure 3C, D).   
    If this effect is translated into microglia in vivo and, in particular, microglia in a 
mouse model of AD, it should result in reduced Aβ accumulation.  To assess this, we 
examined the effect of MCC950 in wildtype and APP/PS1 mice. Aβ-containing plaques 
(indicated with an arrow) were abundant in the brains of APP/PS1 mice (Figure 4A,B) and 
treatment with MCC950 reduced plaque numbers (*p < 0.05; student's t-test for independent 
means).  Predictably the concentrations of soluble Aβ1-40 and Aβ1-42 were increased in tissue 
from APP/PS1 mice (genotype effects ((F1,41)=146.86; p < 0.0001 and ((F1,40)=388.14; p < 
0.0001, respectively; Figure 4C,D); plaque numbers were attenuated in MCC950-treated 
APP/PS1 mice and a significant genotype x treatment interaction was observed in the case of 
Aβ1-40 ((F1,41)=6.62; p = 0.0138). Post-hoc analysis indicated that the significant 
increases in Aβ1-40 and Aβ1-42 (***p < 0.001) were attenuated in MCC950-treated 
APP/PS1 mice (p < 0.01 and p < 0.05 respectively). These data are consistent with the 
proposal that MCC950 increased Aβ phagocytosis in vivo as it did in vitro.  There was 
no significant gender-related difference in plaque numbers in control mice; the mean (± 
SEM) value in male APP/PS1 mice was 25.35 (± 6.23) and the value was 26.17 (± 2.21) in 
female APP/PS1 mice.   
    MCC950 also decreased inflammasome activation in vivo. Thus IL-1β concentration was 
increased in cortical tissue from APP/PS1 mice and this was attenuated in MCC950-treated 
APP/PS1 mice; a significant genotype x treatment interaction was observed ((F1,17)=6.82; p 
= 0.0182; Figure 5A). Post hoc analysis indicated that IL-1β concentration was 
significantly greater in samples from APP/PS1 mice compared with wildtype mice (**p 
< 0.01) and although MCC950 attenuated this increase, it did not reach statistical 
significance. No gender-related change in IL-1β was observed (data not shown). IL-1β 
  
mRNA, which was increased in tissue from APP/PS1 mice, was unchanged by MCC950 
treatment and the same was true of TNFα mRNA and IL-6 mRNA (Figure 5B-D) and in each 
of these cases genotype-related changes were observed ((F1,41)=45.02; p < 0.0001 for IL-
1mRNA, (F1,42)=11.95; p = 0.0013 for TNFα and ((F1,42)=32.36; p < 0.0001 for IL-6). 
Post hoc analysis confirmed that cytokine expression was significantly increased in 
tissue from control-treated APP/PS1, compared with wildtype, mice (***p < 0.001). 
When mRNA expression of IL-1β, TNFα and IL-6 was assessed by gender, the 
genotype-related difference was greater in female mice compared with male mice but 
reached statistical significance only in the case of IL-6 mRNA; the means value in tissue 
from APP/PS1 control-treated male and female mice were 1.30 (± 0.14, SEM) and 2.29 
(± 0.10; p < 0.05; ANOVA). The genotype-related increases in inflammatory cytokines, 
particularly TNFα mRNA, suggest that microglia in the APP/PS1 mice adopt an M1 
phenotype as previously described (Jones et al., 2015; Minogue et al., 2014).  Analysis of 
MRC1 and Arg1 as indicators of the M2 activation state revealed no significant 
genotype- or treatment-related changes (Figure 5C,D) and no gender-related changes 
were observed (not shown). 
    MCC950 also decreased the number of Iba+ cells that stained for caspase 1 in APP/PS1 
mice and statistical analysis indicated that there was a significant interaction between 
genotype and treatment ((F1,28)=10.74; p = 0.0028; Figure 6B).  Post hoc analysis 
indicated that the effect of MCC950 in APP/PS1 mice was significant (++p < 0.01; 
APP/PS1 control vs APP/PS1+MCC950). 
    The evidence also demonstrates that CD11b and CD68 immunoreactivity was increased in 
APP/PS1 mice compared with wildtype mice (Figure 7A,C) and the genotype-related changes 
were statistically significant in the case of both markers ((F1,34)=9.72; p = 0.0037 for CD11b 
and (F1,32)=6.67; p = 0.0146 for CD68; Figure 7B,D). MCC950 treatment attenuated the 
genotype-associated changes but a significant interaction between genotype and treatment 
was observed in the case of CD68 immunoreactivity ((F1,32)=14.25; p = 0.0007; Figure 7D). 
Whereas CD11b and CD68 mRNA expression was significantly increased in tissue from 
APP/PS1 mice, neither was modified in MCC950-treated APP/PS1 mice (data not shown). 
Post hoc analysis indicated that the significant difference in CD11b and CD68 mNRA 
between control-treated wildtype and APP/PS1 mice (**p < 0.01; ***p < 0.001) was 
significantly attenuated in MCC950-treated APP/PS1 mice (+p < 0.05; +++p < 0.001).   
    To evaluate whether these changes were reflected in cognitive function, we assessed 
spontaneous alternation in the T-maze as a measure of working memory and behaviour in the 
2-object novel object recognition test as a measure of recognition memory. APP/PS1 mice 
performed significantly worse than wildtype mice as measured by the percentage of correct 
alternations over a number of trails ((F1,18)=8.03; p = 0.0110; Figure 8A); the effect was not 
observed in MCC950-treated APP/PS1 mice and while a significant treatment effect was 
observed ((F1,18)=4.97; p = 0.0388) the genotype x treatment interaction did not reach 
statistical significance. In the 2-object novel object recognition test, APP/PS1 mice 
performed significantly worse than wildtype mice as assessed by recognition index (Figure 
8B) and treatment with MCC950 significantly attenuated this effect; a significant genotype x 
treatment interaction was observed ((F1,18)=14.95; p = 0.0011). Post hoc analysis indicated 
that performance was significantly worse in control-treated APP/PS1 mice compared 
with wildtype mice (*p < 0.01; ***p < 0.001) and that MCC950-treated APP/PS1 mice 
performed significantly better than control-treated APP/PS1 mice (+p < 0.05; +++p < 
0.001). Mice exhibited no location preference (assessed during the training period; data not 
shown). 
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4. DISCUSSION 
   The significant finding here is that treatment of APP/PS1 mice with the inflammasome 
inhibitor, MCC950, improves cognitive function and reduces microglial activation and Aβ 
pathology. The impact of MCC950 on Aβ pathology results from its ability to block 
production of IL-1β while it promotes Aβ phagocytosis by microglia.   
   MCC950 inhibits LPS+ATP-induced inflammasome activation in mouse bone marrow 
derived macrophages and human monocyte-derived macrophages and blood mononuclear 
cells (Coll et al., 2015) and, here, we report a similar effect in microglia. LPS+ATP markedly 
decreased microglial viability as indicated by analysis of LDH. In contrast, LPS+Aβ, which 
also induced inflammasome activation in microglia as previously described (Murphy et al., 
2014), is a less potent stimulus and did not affect microglial viability. As might be predicted 
from an inflammasome inhibitor, MCC950 inhibited the LPS+Aβ-induced IL-1β release but 
did not affect TNFα or IL-6 release, or IL-1β mRNA (not shown).  The evidence suggests 
that MCC950 blocks assembly of the inflammasome, and this is indicated by its ability to 
prevent co-localization of caspase 1 and ASC in the microglia. At the same time, MCC950 
increased Aβ phagocytosis by microglia. 
   To evaluate the impact of MCC950 in a model of AD, APP/PS1 mice were treated for 3 
months from 12 months, an age at which cognitive changes are evident (Browne et al., 2013) 
and Aβ plaques are well developed.  We show that MCC950 attenuated the genotype-related 
deficits in 2 tests of cognition, and that this was accompanied by a reduction in Aβ plaque 
numbers and soluble Aβ concentration reflecting the ability of MCC950 to increase 
phagocytosis of Aβ.  MCC950 also attenuated the genotype-related increase in IL-1β and co-
localization of ASC and caspase 1 in Iba 1+ cells demonstrating its predicted effect on the 
inflammasome. Indeed the data suggest that the MCC950-related increase in phagocytosis is 
a result of its ability to decrease IL-1β since incubating microglia in the presence of IL-1β 
decreased the phagocytic capability of the cells.  
    Microglial activation is a well-described characteristic of the brain in AD and in animal 
models of AD (Heneka et al., 2016; Jones et al., 2015; Minogue et al., 2014) and the 
genotype-related increases in CD11b and CD68 immunoreactivity reflect this change. 
MCC950 reduced both markers indicating that it restored this measure of microglial 
homeostasis, which may be proxy markers of inflammasome activation. 
    A positive correlation between Aβ pathology and inflammasome activation has been 
identified by Heneka and colleagues who demonstrated that inflammasome activation 
occurred in the brain of APP/PS1 mice and that knocking out NLRP3 reduced IL-1β 
production and amyloid plaque burden (Heneka et al., 2013). This was attributed to the 
skewing of microglia to an M2-like phenotype in NLRP3-deficient APP/PS1 mice.  However, 
in apparent contrast with this, chronic upregulation of human IL-1β in the hippocampus of 
APP/PS1 x IL-1βXAT mice (Shaftel et al., 2007) and in subiculum of 3xTg x IL-1βXAT mice 
(Ghosh et al., 2013) reduced the Aβ load in these brain areas and this was also attributed to 
the predominantly M2-like microglia in these mice (Cherry et al., 2015). In the present 
study, the evidence suggested that microglia in APP/PS1 mice adopt an inflammatory 
phenotype as indicated by the increased expression of inflammatory cytokines and no 
change in MRC1 and Arg1, which are indicative of the M2 phenotype.  
   The twin effects of MCC950 in inhibiting IL-1β processing and increasing phagocytosis of 
Aβ are consistent with evidence that suggests IL-1β may inhibit phagocytosis. An anti-IL-1R 
blocking antibody has been reported to reduce insoluble Aβ1-42, fibrillar Aβ oligomers and 
large Aβ-containing plaques in brain tissue from 3xTg mice (Kitazawa et al., 2011) and IL-
1β+ microglia prepared from APP/PS1 mice had reduced Aβ compared with IL-1β− microglia 
(Saresella et al., 2016). The decrease in brain IL-1β in APP/PS1/NLRP3−/−, was also 
  
accompanied by evidence of increased phagocytosis of Aβ by microglia, assessed by 
evaluating the presence of the amyloid dye methoxy-X04 using flow cytometry (Heneka et 
al., 2013).  
    The data point to a potential therapeutic value of MCC950 in AD, adding to evidence of its 
value in other conditions where inflammation is key (Coll et al., 2015), although it has to be 
acknowledged that translation of efficacy from an animal model to the human disease is a 
very significant step. Despite this, MCC950 has undergone some clinical testing as it was 
originally developed as a treatment for arthritis and it has the advantage that it can be 
delivered orally.  The possibility that it may be useful in early-onset disease is particularly 
interesting. 
 
5. CONCLUSIONS 
   Our evidence shows that MCC950, by inhibiting inflammasome activation and increasing 
phagocytic capability of microglia, reduces Aβ pathology and consequently improves 
cognition.  This identifies inflammasome activation as a contributory factor in driving the 
pathology and associated loss of function and establishes the inflammasome is an important 
therapeutic target in AD. 
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FIGURE LEGENDS 
Figure 1. MCC950 attenuates the LPS+Aβ-induced increase in IL-1β without affecting 
cell viability 
Microglia from neonatal mice were incubated with LPS (1µg/ml), MCC950 (100µM) was 
added at 2.5h and ATP (5mM) at 3h and incubation continued for 5h.  Alternatively cells 
were incubated with LPS (1µg/ml), MCC950 (100µM) was added at 4h and Aβ (10µM) at 
4.5h and incubation continued for 24h. Supernatant samples were assessed for cytokines and 
LDH and also for pro- and cleaved IL-1β by western immunoblotting.   
A,B. A significant MCC950 x LPS+ATP interaction ((F1,20)=27.13; p < 0.0001), and a 
significant MCC950 x LPS+Aβ interaction ((F1,8)=14.31; p = 0.0043; 2 way ANOVA), was 
observed. Post hoc analysis indicated that the significant effects of LPS+ATP or LPS+Aβ 
(***p < 0.001) were attenuated by MCC950 (+++p < 0.001 and ++p < 0.01 respectively). 
C. LPS+Aβ increased cleaved IL-1β and this was attenuated by MCC950 whereas no 
MCC950-associated effect on pro-IL-1β was observed.   
D,E. LPS+ATP increased LDH and this was blocked by MCC950 and there was a significant 
MCC950 x LPS+Aβ interaction ((F1,8)=70.51; p < 0.0001) and post hoc analysis indicated 
that the significant effects of LPS+ATP (***p < 0.001) was attenuated by MCC950 (+++p 
< 0.001). LPS+Aβ exerted no effect on LDH either alone or with MCC950.  
F,G. LPS+Aβ increased supernatant concentrations of TNFα (F) and IL-6 (G) reflecting 
significant treatment effects; ( (F1,8)=59.11; p < 0.0001 and ((F1,8)=130.88; p < 0.0001, 
respectively) and post hoc analysis revealed significant LPS+Aβ effects (**p < 0.01; ***p 
< 0.001) that were not affected by MCC950.  
Data are presented for 3-6 replicates across 2 separate experiments and samples were 
assessed in triplicate. 
 
  
Figure 2. MCC950 prevents the LPS+Aβ-induced increase in caspase 1+ ASC+ microglia 
Microglia from neonatal mice were plated on poly-D-lysine-coated coverslips and incubated 
with LPS (1µg/ml), MCC950 (100µM) was added at 4h and Aβ (10 µM) at 4.5h. Incubation 
continued for 24h, cells were fixed in 4% PFA and stained for caspase 1 p20 and ASC as 
described in the methods.  
A. Sample images are presented showing confocal fluorescence images (40x) of 
representative fields stained for caspase1 (red) and ASC (green).  
B. Analysis of mean data revealed a significant LPS+Aβ x MCC950 interaction 
(*(F1,10)=5.29; p = 0.044) in caspase 1 immunoreactivity and a significant difference 
between LPS+Aβ-induced changes in the presence and absence of MCC950 (+p < 0.05: 
Bonferroni test).   
C. Similar changes were evident with caspase 1+ASC+ cells but the data did not reach 
statistical significance. Values for B and C are means ± SEM (n=3 or 4). 
 
Figure 3. MCC950 increases Aβ phagocytosis in LPS+Aβ-stimulated microglia  
Microglia were prepared as described in the legend for Figure 2. Cells were stained for Iba1 
and Aβ as described in the methods.  The panel shows confocal fluorescence images at 63X 
magnification.  
A. The sample image shows the presence of Aβ (green) in Iba1+ (red) in a cell that was 
incubated in LPS+Aβ with MCC950. The insert highlights Aβ uptake by an Iba1+ cell.  The 
cell nucleus is stained pink and the white arrows indicate Aβ that has been engulfed by 
the cell, which was verified by confocal imaging.  
B. Analysis of mean data (n = 4) revealed a significant effect of MCC950 (§(F1,12)=7.93; 
p=0.0156).  C.  Sample images show that Aβ was engulfed by control Iba1+ cells (white 
arrows), this was reduced in IL-1β-treated cells.   
D. Analysis of the mean data (from a total of 402 cells examined) indicated that IL-1β 
significantly decreased the percentage of Iba+ cells that stained positively for  Aβ (***p < 
0.001; student's t-test for independent means).  
 
Figure 4.  MCC950 reduces Aβ pathology in APP/PS1 mice. 
Cryostat sections of brain tissue were stained for Aβ plaques using Congo red and Aβ plaque 
numbers in the hippocampus were quantified.  
A. Representative images of Congo red staining in the hippocampus of wildtype and 
APP/PS1 mice are shown. The red arrows highlight some Aβ plaques. 
B. There was a significant reduction in the number of plaques present in the hippocampus of 
APP/PS1 mice that received MCC950 compared with control-treated APP/PS1 mice (*p < 
0.05; student’s t-test for independent means). Data were obtained from 3 slides with 3 
sections/slide for each mouse and are means ± SEM; n=11-13). 
C,D. The concentrations of Aβ1-40 (C) and Aβ1-42 (D), assessed by ELISA (see methods) were 
significantly increased in cortical tissue from APP/PS1, compared with wildtype, mice 
(+++genotype effects ((F1,41)=146.86; p < 0.0001 and ((F1,40)=388.14; p < 0.0001, 
respectively.  Treatment with MCC950 attenuated the genotype-associated changes and a 
significant genotype x treatment interaction was observed in Aβ1-40 (*(F1,41)=6.62; p = 
0.0138). Post-hoc analysis indicated that the significant increases in Aβ1-40 and Aβ1-42 
(***p < 0.001) were attenuated in MCC950-treated APP/PS1 mice (p < 0.01 and p < 0.05 
respectively).  Values are means ± SEM of 11-13 replicates. 
 
Figure 5. MCC950 attenuates the genotype-related increase in IL-1β. 
  
A. Homogenate from cortical tissue of control- and MCC950-treated wildtype and APP/PS1 
mice was assessed for IL-1β concentration by ELISA.  The genotype-related increase in 
concentration of IL-1β was attenuated in MCC950-treated APP/PS1 mice and a significant 
genotype x treatment interaction was observed (*(F1,17)=6.82; p = 0.0182. Post hoc analysis 
indicated a significant increase in IL-1β in control-treated APP/PS1, compared with 
wildtype, mice (**p < 0.01) and values are means ± SEM (n = 5-6).  
B-D. The genotype-related increases in mRNA expression of IL-1β (+++(F1,41)=45.02; p < 
0.0001), TNFα (+++ (F1,42)=11.95; p = 0.0013) and IL-6 (+++ (F1,42)=32.36; p < 0.0001) 
were not affected by MCC950 treatment. Post hoc analysis confirmed that cytokine 
expression was significantly increased in tissue from control-treated APP/PS1, 
compared with wildtype, mice (***p < 0.001). 
E,F. No significant genotype- or treatment-related changes were observed in either 
MRC1 or Arg1 mRNA.  For C-F mean values ± SEM of 11-13 samples are presented. 
 
Figure 6. MCC950 decreases caspase 1 in microglia of APP/PS1 mice. 
MCC950 decreased the number of Iba+ cells that stained positively for caspase 1 in APP/PS1 
mice (A) and statistical analysis of the data revealed a significant interaction between 
genotype and treatment (B; (F1,28)=10.74; p = 0.0028) and post hoc analysis indicated a 
significant difference between the APP/PS1 control and APP/PS1+MCC950 treatment 
groups (++p < 0.01; n=8).  
 
Figure 7.  MCC950 attenuates the genotype-related increases in microglial activation. 
Sections of brain tissue were assessed for CD11b and CD68 immunoreactivity.   
CD11b immunoreactivity (A,B) and CD68 immunoreactivity (C,D) were markedly increased 
in sections from control-treated APP/PS1 mice compared with wildtype mice  and significant 
genotype changes were observed ((F1,34)=9.72; p = 0.0037 for CD11b and ((F1,32)=6.67; p 
= 0.0146 for CD68).  A significant interaction between genotype and treatment was observed 
in CD68 immunoreactivity (***(F1,32)=14.25; p = 0.0007). Post hoc analysis indicated 
that the significant difference in CD11b and CD68 mNRA between control-treated 
wildtype and APP/PS1 mice (**p < 0.01; ***p < 0.001) was significantly attenuated in 
MCC950-treated APP/PS1 mice (+p < 0.05; +++p < 0.001).  Data in B and D are means ± 
SEM (n=12).  
 
Figure 8.  MCC950 improves cognitive function.  
Control- and MCC950-treated wildtype and APP/PS1 mice were assessed spontaneous 
alternation in the T-maze, where performance was assessed by the number of correct 
alternations made over 8 trials, and for performance in a 2-object novel object recognition 
test where the ability of mice to recognize a novel object was assessed by the time spent 
explorating this, compared with a familiar, object.  
A. Control-treated APP/PS1 mice performed significantly worse in the spontaneous 
alternation test than wildtype mice (+genotype effect: (F1,18)=8.03; p = 0.0110) but 
MCC950-treated APP/PS1 mice were significant better (treatment effect: (F1,18)=4.97; p = 
0.0388). Post hoc analysis indicated that performance was significantly worse in control-
treated APP/PS1 mice compared with wildtype mice (*p < 0.01) and that MCC950 
significantly attenuated the effect of genotype (+p < 0.05). 
B. Recognition index was used as an indicator of the relative time mice spent exploring a 
novel, compared with a familiar, object.  This value was reduced in control-treated APP/PS1, 
compared with wildtype, mice and a significant genotype x treatment interaction was 
observed (**(F1,18)=14.95; p = 0.0011). Post hoc analysis indicated that performance 
was significantly poorer in control-treated APP/PS1 mice compared with control-
  
treated wildtype mice (***p < 0.001) and that MCC950 treatment improved 
performance in APP/PS1 mice (+++p < 0.001). Data are presented as means ± SEM (n = 
4-6). 
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Highlights 
• The small molecule inhibitor of the inflammasome, MC950, attenuates Aβ+LPS-induced 
inflammasome activation in microglia. 
• It increases phagocytosis of Aβ by microglia in vitro 
• Oral administration of MC950, reduces Aβ accumulation in APP/PS1 mice 
• This is accompanied by improved cognitive function and decreased neuroinflammation  	  
